Cargando…
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
Subcutaneous daratumumab plus bortezomib/cyclophosphamide/dexamethasone (VCd; D-VCd) improved outcomes versus VCd for patients with newly diagnosed immunoglobulin light-chain (AL) amyloidosis in the phase 3 ANDROMEDA study. We report a subgroup analysis of Asian patients (Japan; Korea; China) from A...
Autores principales: | Suzuki, Kenshi, Wechalekar, Ashutosh D., Kim, Kihyun, Shimazaki, Chihiro, Kim, Jin Seok, Ikezoe, Takayuki, Min, Chang-Ki, Zhou, Fude, Cai, Zhen, Chen, Xiaonong, Iida, Shinsuke, Katoh, Nagaaki, Fujisaki, Tomoaki, Shin, Ho-Jin, Tran, NamPhuong, Qin, Xiang, Vasey, Sandra Y., Tromp, Brenda, Weiss, Brendan M., Comenzo, Raymond L., Kastritis, Efstathios, Lu, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998577/ https://www.ncbi.nlm.nih.gov/pubmed/36862168 http://dx.doi.org/10.1007/s00277-023-05090-z |
Ejemplares similares
-
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial
por: Minnema, Monique C., et al.
Publicado: (2022) -
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019) -
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023) -
Andromeda breakthrough /
por: Hoyle, Fred
Publicado: (1970) -
The Andromeda galaxy
por: Hodge, Paul
Publicado: (1992)